These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 113077)

  • 1. Combination of radiotherapy and razoxane (ICRF 159) for chondrosarcoma.
    Ryall RD; Bates T; Newton KA; Hellmann K
    Cancer; 1979 Sep; 44(3):891-5. PubMed ID: 113077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of radiotherapy with and without razoxane (ICRF 159) in the treatment of soft tissue sarcomas.
    Hellmann K; Ryall RD; Macdonald E; Newton KA; James SE; Jones S
    Cancer; 1978 Jan; 41(1):100-7. PubMed ID: 414829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of blast cell crisis of chronic myeloid leukemia with ICRF-159 (razoxane).
    Bakowski MT; Brearley RL; Wrigley PF
    Cancer Treat Rep; 1979; 63(11-12):2085-7. PubMed ID: 294308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined radiotherapy and razoxane in the treatment of chondrosarcomas and chordomas.
    Rhomberg W; Eiter H; Böhler F; Dertinger S
    Anticancer Res; 2006; 26(3B):2407-11. PubMed ID: 16821624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical experiences with radiotherapy and ICRF 159 in sarcomas].
    Rhomberg W; Mesche E; Gefeller D; Hassenstein E
    Strahlentherapie Sonderb; 1978; 75():110-4. PubMed ID: 400195
    [No Abstract]   [Full Text] [Related]  

  • 6. Radiotherapy and ICRF 159 in the treatment of soft tissue sarcomas.
    Ryall RD
    Int J Radiat Oncol Biol Phys; 1978; 4(1-2):133-4. PubMed ID: 632140
    [No Abstract]   [Full Text] [Related]  

  • 7. Radiotherapy combined with ICRF 159 (NSC 129943).
    Rhomberg WU
    Int J Radiat Oncol Biol Phys; 1978; 4(1-2):121-6. PubMed ID: 204615
    [No Abstract]   [Full Text] [Related]  

  • 8. Phase II evaluation of dibromodulcitol, ICRF-159, and maytansine for sarcomas.
    Borden EC; Ash A; Enterline HT; Rosenbaum C; Laucius JF; Paul AR; Falkson G; Lerner H
    Am J Clin Oncol; 1982 Aug; 5(4):417-20. PubMed ID: 6956236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A trial of razoxane (ICRF-159) in patients with prior therapy for Hodgkin's lymphoma.
    Corder MP; McFadden DB; Bell SJ
    Cancer; 1984 Oct; 54(8):1496-8. PubMed ID: 6383594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Limited activity of ICRF-159 in advanced acute leukemia.
    Bakowski MT; Prentice HG; Lister TA; Malpas JS; McElwain TJ; Powles RL
    Cancer Treat Rep; 1979 Jan; 63(1):127-9. PubMed ID: 369684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I trial of cisplatin and razoxane (ICRF-159) (NSC #119875) in advanced squamous cell carcinoma of the cervix. A Gynecologic Oncology Group Pilot Study.
    Bonomi P; Yordan E; Blessing JA
    Am J Clin Oncol; 1988 Feb; 11(1):1-2. PubMed ID: 3277372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ICRF-159 (razoxane) in patients with advanced nonsquamous cell carcinoma of the cervix. A Gynecologic Oncology Group study.
    Homesley HD; Blessing JA; Berman M
    Am J Clin Oncol; 1986 Aug; 9(4):325-6. PubMed ID: 3751970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Further experience with rezoxane (ICRF 159; -- NSC --129943) in treating Kaposi's sarcoma.
    Olweny CL; Sikyewunda W; Otim D
    Oncology; 1980; 37(3):174-6. PubMed ID: 7360489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of ICRF-159 versus combination cis-dichlorodiammineplatinum(II) and DTIC in patients with disseminated malignant melanoma.
    Ahmann DL; Edmonson JH; Frytak S; Kvols LK; Bisel HF; Rubin J
    Cancer Treat Rep; 1978 Jan; 62(1):151-3. PubMed ID: 626995
    [No Abstract]   [Full Text] [Related]  

  • 15. [Combined treatment of lung carcinoma. Report on a prospective randomized study with radiotherapy and ICRF 159 (1,2-(3,5-dioxopiperazines-lyl)propane) (author's transl)].
    Hassenstein E; Rhomberg W
    Med Klin; 1977 Feb; 72(5):171-5. PubMed ID: 403395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ICRF-159 (razoxane) in patients with advanced adenocarcinoma of the endometrium. A Gynecologic Oncology Group Study.
    Homesley HD; Blessing JA; Conroy J; Hatch K; DiSaia PJ; Twiggs LB
    Am J Clin Oncol; 1986 Feb; 9(1):15-7. PubMed ID: 3953488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of radiation and razoxane (ICRF 159) in vivo.
    Hellmann K; Grimshaw MB; Hutchinson GE
    Int J Radiat Oncol Biol Phys; 1978; 4(1-2):109-13. PubMed ID: 632139
    [No Abstract]   [Full Text] [Related]  

  • 18. A clinical evaluation of ICRF 159 as a radiosensitising agent.
    Bates T
    Int J Radiat Oncol Biol Phys; 1978; 4(1-2):127-31. PubMed ID: 344288
    [No Abstract]   [Full Text] [Related]  

  • 19. ICRF-159 (razoxane) in the treatment of pediatric solid tumors: a Southwest Oncology Group study.
    Dyment PG; Starling KA; Land VJ; Cangir A; Komp DM; Sexauer CL
    Cancer Treat Rep; 1979 Aug; 63(8):1397-8. PubMed ID: 476712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ICRF-187 and razoxane in cancer treatment.
    Lancet; 1987 Sep; 2(8561):721. PubMed ID: 2888947
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.